stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Return on equity
Tarsus Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 September 2026 was −319.8%, down 296.4 percentage points from fiscal 2025 (−23.4%). Over the past ten years it has ranged from −69.7% (fiscal 2023) to 126.9% (fiscal 2019); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −23.4% | 31.44 |
| FY2024 | −54.8% | 14.88 |
| FY2023 | −69.7% | (35.18) |
| FY2022 | −34.5% | (26.22) |
| FY2021 | −8.31% | 25.21 |
| FY2020 | −33.5% | (160.44) |
| FY2019 | 126.9% | 91.07 |
| FY2018 | 35.9% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.3% |
| DNLI Denali Therapeutics Inc. compare | −33.9% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| TARS Tarsus Pharmaceuticals, Inc. | −319.8% |
| CELC Celcuity, Inc. compare | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement